title: Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
authors.affiliation: 1000 Veteran Avenue Rehabilitation Centre, Room 32-59, Los Angeles, CA 90024, USA. defurst@mednet.ucla.edu
authors.forename: D E
authors.initials: DE
authors.lastname: Furst
authors.forename: F C
authors.initials: FC
authors.lastname: Breedveld
authors.forename: J R
authors.initials: JR
authors.lastname: Kalden
authors.forename: J S
authors.initials: JS
authors.lastname: Smolen
authors.forename: G R
authors.initials: GR
authors.lastname: Burmester
authors.forename: J W J
authors.initials: JW
authors.lastname: Bijlsma
authors.forename: M
authors.initials: M
authors.lastname: Dougados
authors.forename: P
authors.initials: P
authors.lastname: Emery
authors.forename: E C
authors.initials: EC
authors.lastname: Keystone
authors.forename: L
authors.initials: L
authors.lastname: Klareskog
authors.forename: P J
authors.initials: PJ
authors.lastname: Mease
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D019317:Evidence-Based Medicine; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein; D012216:Rheumatic Diseases / Q000188:drug therapy*; D012795:Sialoglycoproteins / Q000037:antagonists & inhibitors*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D018501:Antirheumatic Agents; C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D012795:Sialoglycoproteins; D014409:Tumor Necrosis Factor-alpha